Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

SARS-CoV-2 vaccine is considered the primary health strategy able to end the current COVID-19 pandemic. This viral infection impacts more severely solid organ transplant recipients (SOTRs) than general population, but the effect of vaccination in this subgroup of immunosuppressed patients is not known due to their exclusion from vaccination trials. Preliminary reports suggest a lower antibody production after BNT162b2 Pfizer/BioNTech mRNA-vaccine1,2,3,4 , but no data are currently available on the elicited virus-specific T cell responses.

[1]  D. Schwartz,et al.  Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus , 2021, American Journal of Transplantation.

[2]  S. Adamopoulos,et al.  Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients , 2021, American Journal of Transplantation.

[3]  M. Ison,et al.  The future of SARS-CoV-2 vaccines in transplant recipients: To be determined , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  D. Segev,et al.  Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. , 2021, JAMA.

[5]  M. Ison,et al.  Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.